Medical - Instruments & Supplies
Compare Stocks
4 / 10Stock Comparison
LUCY vs PRPH vs VSCO vs QDEL
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
Apparel - Retail
Medical - Instruments & Supplies
LUCY vs PRPH vs VSCO vs QDEL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Instruments & Supplies | Drug Manufacturers - Specialty & Generic | Apparel - Retail | Medical - Instruments & Supplies |
| Market Cap | $6M | $5M | $3.80B | $733M |
| Revenue (TTM) | $2M | $1M | $6.39B | $2.66B |
| Net Income (TTM) | $-8M | $-42M | $171M | $-1.21B |
| Gross Margin | 22.8% | 191.4% | 36.7% | 56.6% |
| Operating Margin | -341.4% | -25.0% | 4.9% | -37.0% |
| Forward P/E | — | — | 17.4x | 6.4x |
| Total Debt | $0.00 | $25M | $2.70B | $2.80B |
| Cash & Equiv. | $3M | $678K | $227M | $170M |
LUCY vs PRPH vs VSCO vs QDEL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Aug 22 | May 26 | Return |
|---|---|---|---|
| Innovative Eyewear,… (LUCY) | 100 | 1.7 | -98.3% |
| ProPhase Labs, Inc. (PRPH) | 100 | 2.0 | -98.0% |
| Victoria's Secret &… (VSCO) | 100 | 142.2 | +42.2% |
| QuidelOrtho Corpora… (QDEL) | 100 | 13.6 | -86.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: LUCY vs PRPH vs VSCO vs QDEL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
LUCY is the #2 pick in this set and the best alternative if growth exposure and sleep-well-at-night is your priority.
- Rev growth 42.0%, EPS growth 59.0%, 3Y rev CAGR 33.3%
- Lower volatility, beta 1.52, current ratio 12.52x
- Beta 1.52, current ratio 12.52x
- 42.0% revenue growth vs PRPH's -84.7%
PRPH is the clearest fit if your priority is income & stability and long-term compounding.
- Dividend streak 1 yrs, beta 2.28
- 37.5% 10Y total return vs VSCO's 11.9%
VSCO carries the broadest edge in this set and is the clearest fit for quality and momentum.
- 2.7% margin vs PRPH's -38.7%
- +147.1% vs QDEL's -58.3%
- 3.6% ROA vs LUCY's -76.8%, ROIC 7.7% vs -153.6%
QDEL is the clearest fit if your priority is value.
- Lower P/E (6.4x vs 17.4x)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 42.0% revenue growth vs PRPH's -84.7% | |
| Value | Lower P/E (6.4x vs 17.4x) | |
| Quality / Margins | 2.7% margin vs PRPH's -38.7% | |
| Stability / Safety | Beta 1.52 vs QDEL's 2.59 | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +147.1% vs QDEL's -58.3% | |
| Efficiency (ROA) | 3.6% ROA vs LUCY's -76.8%, ROIC 7.7% vs -153.6% |
LUCY vs PRPH vs VSCO vs QDEL — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
LUCY vs PRPH vs VSCO vs QDEL — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
VSCO leads in 3 of 6 categories
QDEL leads 1 • PRPH leads 1 • LUCY leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
VSCO leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
VSCO is the larger business by revenue, generating $6.4B annually — 5933.1x PRPH's $1M. VSCO is the more profitable business, keeping 2.7% of every revenue dollar as net income compared to PRPH's -38.7%. On growth, LUCY holds the edge at +163.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $2M | $1M | $6.4B | $2.7B |
| EBITDAEarnings before interest/tax | -$8M | -$22M | $561M | -$649M |
| Net IncomeAfter-tax profit | -$8M | -$42M | $171M | -$1.2B |
| Free Cash FlowCash after capex | -$8M | -$23M | $309M | -$75M |
| Gross MarginGross profit ÷ Revenue | +22.8% | +191.4% | +36.7% | +56.6% |
| Operating MarginEBIT ÷ Revenue | -3.4% | -25.0% | +4.9% | -37.0% |
| Net MarginNet income ÷ Revenue | -3.3% | -38.7% | +2.7% | -45.6% |
| FCF MarginFCF ÷ Revenue | -3.3% | -21.1% | +4.8% | -2.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +163.5% | -71.9% | +9.3% | -10.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +61.6% | +54.3% | +35.2% | -6.1% |
Valuation Metrics
QDEL leads this category, winning 3 of 4 comparable metrics.
Valuation Metrics
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $6M | $5M | $3.8B | $733M |
| Enterprise ValueMkt cap + debt − cash | $3M | $29M | $6.3B | $3.4B |
| Trailing P/EPrice ÷ TTM EPS | -0.20x | -0.05x | 23.31x | -0.65x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 17.37x | 6.45x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | 11.09x | — |
| Price / SalesMarket cap ÷ Revenue | 3.43x | 0.74x | 0.61x | 0.27x |
| Price / BookPrice ÷ Book value/share | 0.17x | 0.31x | 5.78x | 0.38x |
| Price / FCFMarket cap ÷ FCF | — | — | 15.40x | — |
Profitability & Efficiency
VSCO leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
VSCO delivers a 24.9% return on equity — every $100 of shareholder capital generates $25 in annual profit, vs $-6 for PRPH. QDEL carries lower financial leverage with a 1.46x debt-to-equity ratio, signaling a more conservative balance sheet compared to VSCO's 4.06x. On the Piotroski fundamental quality scale (0–9), VSCO scores 7/9 vs PRPH's 1/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -82.3% | -6.1% | +24.9% | -56.3% |
| ROA (TTM)Return on assets | -76.8% | -63.5% | +3.6% | -20.7% |
| ROICReturn on invested capital | -153.6% | -59.4% | +7.7% | -13.6% |
| ROCEReturn on capital employed | -107.8% | -75.6% | +10.1% | -18.0% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 1 | 7 | 6 |
| Debt / EquityFinancial leverage | — | 3.34x | 4.06x | 1.46x |
| Net DebtTotal debt minus cash | -$3M | $24M | $2.5B | $2.6B |
| Cash & Equiv.Liquid assets | $3M | $678,000 | $227M | $170M |
| Total DebtShort + long-term debt | $0 | $25M | $2.7B | $2.8B |
| Interest CoverageEBIT ÷ Interest expense | — | -7.96x | 4.24x | -5.18x |
Total Returns (Dividends Reinvested)
VSCO leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in VSCO five years ago would be worth $11,188 today (with dividends reinvested), compared to $89 for LUCY. Over the past 12 months, VSCO leads with a +147.1% total return vs QDEL's -58.3%. The 3-year compound annual growth rate (CAGR) favors VSCO at 21.0% vs LUCY's -73.1% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -7.9% | -66.7% | -10.9% | -62.6% |
| 1-Year ReturnPast 12 months | -41.7% | -58.0% | +147.1% | -58.3% |
| 3-Year ReturnCumulative with dividends | -98.1% | -97.1% | +77.4% | -87.8% |
| 5-Year ReturnCumulative with dividends | -99.1% | -63.2% | +11.9% | -91.1% |
| 10-Year ReturnCumulative with dividends | -99.1% | +37.5% | +11.9% | -34.9% |
| CAGR (3Y)Annualised 3-year return | -73.1% | -69.4% | +21.0% | -50.4% |
Risk & Volatility
Evenly matched — LUCY and VSCO each lead in 1 of 2 comparable metrics.
Risk & Volatility
LUCY is the less volatile stock with a 1.52 beta — it tends to amplify market swings less than QDEL's 2.59 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. VSCO currently trades 71.1% from its 52-week high vs PRPH's 6.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.52x | 2.28x | 2.23x | 2.59x |
| 52-Week HighHighest price in past year | $4.97 | $1.84 | $66.89 | $38.99 |
| 52-Week LowLowest price in past year | $0.95 | $0.07 | $17.53 | $10.22 |
| % of 52W HighCurrent price vs 52-week peak | +21.1% | +6.5% | +71.1% | +27.6% |
| RSI (14)Momentum oscillator 0–100 | 47.6 | 56.8 | 51.4 | 35.2 |
| Avg Volume (50D)Average daily shares traded | 76K | 105K | 2.3M | 2.2M |
Analyst Outlook
PRPH leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: VSCO as "Buy", QDEL as "Buy". Consensus price targets imply 57.8% upside for QDEL (target: $17) vs 17.1% for VSCO (target: $56).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — | Buy | Buy |
| Price TargetConsensus 12-month target | — | — | $55.67 | $17.00 |
| # AnalystsCovering analysts | — | — | 14 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 1 | — | 0 |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.3% | 0.0% |
VSCO leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). QDEL leads in 1 (Valuation Metrics). 1 tied.
LUCY vs PRPH vs VSCO vs QDEL: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is LUCY or PRPH or VSCO or QDEL a better buy right now?
For growth investors, Innovative Eyewear, Inc.
(LUCY) is the stronger pick with 42. 0% revenue growth year-over-year, versus -84. 7% for ProPhase Labs, Inc. (PRPH). Victoria's Secret & Co. (VSCO) offers the better valuation at 23. 3x trailing P/E (17. 4x forward), making it the more compelling value choice. Analysts rate Victoria's Secret & Co. (VSCO) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — LUCY or PRPH or VSCO or QDEL?
On forward P/E, QuidelOrtho Corporation is actually cheaper at 6.
4x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — LUCY or PRPH or VSCO or QDEL?
Over the past 5 years, Victoria's Secret & Co.
(VSCO) delivered a total return of +11. 9%, compared to -99. 1% for Innovative Eyewear, Inc. (LUCY). Over 10 years, the gap is even starker: PRPH returned +37. 5% versus LUCY's -99. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — LUCY or PRPH or VSCO or QDEL?
By beta (market sensitivity over 5 years), Innovative Eyewear, Inc.
(LUCY) is the lower-risk stock at 1. 52β versus QuidelOrtho Corporation's 2. 59β — meaning QDEL is approximately 71% more volatile than LUCY relative to the S&P 500. On balance sheet safety, QuidelOrtho Corporation (QDEL) carries a lower debt/equity ratio of 146% versus 4% for Victoria's Secret & Co. — giving it more financial flexibility in a downturn.
05Which is growing faster — LUCY or PRPH or VSCO or QDEL?
By revenue growth (latest reported year), Innovative Eyewear, Inc.
(LUCY) is pulling ahead at 42. 0% versus -84. 7% for ProPhase Labs, Inc. (PRPH). On earnings-per-share growth, the picture is similar: Innovative Eyewear, Inc. grew EPS 59. 0% year-over-year, compared to -166. 3% for ProPhase Labs, Inc.. Over a 3-year CAGR, LUCY leads at 33. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — LUCY or PRPH or VSCO or QDEL?
Victoria's Secret & Co.
(VSCO) is the more profitable company, earning 2. 6% net margin versus -788. 2% for ProPhase Labs, Inc. — meaning it keeps 2. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VSCO leads at 5. 0% versus -570. 6% for PRPH. At the gross margin level — before operating expenses — QDEL leads at 46. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is LUCY or PRPH or VSCO or QDEL more undervalued right now?
On forward earnings alone, QuidelOrtho Corporation (QDEL) trades at 6.
4x forward P/E versus 17. 4x for Victoria's Secret & Co. — 10. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for QDEL: 57. 8% to $17. 00.
08Which pays a better dividend — LUCY or PRPH or VSCO or QDEL?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is LUCY or PRPH or VSCO or QDEL better for a retirement portfolio?
For long-horizon retirement investors, Innovative Eyewear, Inc.
(LUCY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. QuidelOrtho Corporation (QDEL) carries a higher beta of 2. 59 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LUCY: -99. 1%, QDEL: -34. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between LUCY and PRPH and VSCO and QDEL?
These companies operate in different sectors (LUCY (Healthcare) and PRPH (Healthcare) and VSCO (Consumer Cyclical) and QDEL (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: LUCY is a small-cap high-growth stock; PRPH is a small-cap quality compounder stock; VSCO is a small-cap quality compounder stock; QDEL is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.